Invasive procedures to biopsy tissue from cancer-tainted organs could be replaced by simply taking samples from a tiny “decoy” implanted just beneath the skin, University of Michigan researchers have demonstrated in mice.
These devices have a knack for attracting cancer cells traveling through the body. In fact, they can even pick up signs that cancer is preparing to spread, before cancer cells arrive.
“Biopsying an organ like the lung is a risky procedure that’s done only sparingly,” said Lonnie Shea, the William and Valerie Hall Chair of biomedical engineering at U-M. “We place these scaffolds right under the skin, so they’re readily accessible.”
The ease of access would also allow doctors to monitor the effectiveness of cancer treatments closer to real time.
The U-M team’s most recent work appears in Cancer Research, a publication of the American Association for Cancer Research.
Biopsies of the scaffold allowed researchers to analyze 635 genes present in the captured cancer cells. From these genes, the team identified ten that could predict whether a mouse was healthy, if it had a cancer that had not begun to spread yet, or if a cancer was present and had begun to spread. They could do that all without the need for an invasive biopsy of an organ.
The gene expression obtained at the scaffold had distinct patterns relative to cells from the blood, which are obtained through a technique known as liquid biopsy. These differences highlight that the tissue in these traps provides unique information that correlates with disease progression.
The researchers have demonstrated that the synthetic scaffolds work with multiple types of cancers in mice, including pancreatic cancer. They work by luring immune cells, which, in turn, attract cancer cells.
“When we started off, the idea was that we would biopsy the scaffold and look for tumor cells that had followed the immune cells there,” Shea said. “But we realized that by analyzing the immune cells that gather first, we can detect the cancer before it’s spreading.”
In treating cancer, early detection is key.
“Currently, early signs of metastasis can be difficult to detect,” said Jacqueline Jeruss, an associate professor of surgery and biomedical engineering and a co-author of the study. “Imaging may be done once a patient experiences symptoms, but that implies the number of cancer cells may already be substantial. Improved detection methods are needed to identify metastasis at a point when targeted treatments can have a significant beneficial impact on slowing disease progression.”
The immune cells allowed researchers to identify whether treatments were effective in the mice and which subjects were sensitive or resistant to treatment.
The decoy’s ability to draw immune and cancer cells can also bolster the treatment itself. In previous research, the devices demonstrated an ability to slow the growth of metastatic breast cancer tumors in mice, by reducing the number of cancer cells that can reach those tumors.
In the future, Shea envisions that the scaffolds could be outfitted with sensors and Bluetooth technology that could deliver information in real time without the need for a biopsy.
Learn more: Implantable cancer traps could provide earlier diagnosis, help monitor treatment
The Latest on: Biopsies
[google_news title=”” keyword=”biopsies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Biopsies
- Liquid Biopsy Market to be valued at US$ 4,126 Million from 2022 to 2032 | Says Future Market Insightson June 6, 2023 at 11:45 pm
The global liquid biopsy market is anticipated to create lucrative growth opportunities over the projection period by exhibiting a total CAGR of 13.49% from 2022 to 2032. The global market is expected ...
- Importance and Determinants of Gleason Score Undergrading on Biopsy Sample of Prostate Cancer in a Population-based Studyon June 4, 2023 at 5:00 pm
Background: In this population-based study, we investigated the degree of concordance between Gleason scores obtained from prostate biopsies and those obtained from prostatectomy specimens ...
- 'Liquid biopsies' could revolutionise treatment for cancer patientson June 4, 2023 at 12:12 am
A medical research study involving cancer patients could lead to “revolutionary” changes in the way the disease is managed in the future, according to experts. The University of Edinburgh has been ...
- Global Needle Market Report 2023: Increasing Minimally Invasive Biopsies Fuel the Sectoron May 29, 2023 at 1:53 am
Dublin, May 29, 2023 (GLOBE NEWSWIRE) -- The "Global Needle Market (2023-2028) by Product, Type, Delivery Mode, Material, Applications, End-Users, and Geography, Competitive Analysis, Impact of ...
- Biopsy: What you need to knowon May 24, 2023 at 5:00 pm
Together, they mean “to view life.” This article covers the different types and uses of biopsies and what a person should expect from the procedure. A biopsy involves a pathologist examining ...
- MRI fusion biopsy systems for diagnosing prostate canceron May 23, 2023 at 11:36 pm
3.1 Patient experts explained that technologies that help correctly diagnose prostate cancer could reduce the number of missed cancers and repeat biopsies. Overtreatment was highlighted as a ...
- MRI fusion biopsy systems for diagnosing prostate canceron May 23, 2023 at 5:00 pm
This informs treatment options (such as active surveillance, radical prostatectomy and radiotherapy). 2.2 Targeted biopsies, which take only a small number of tissue samples or cores, are done for ...
- Bleeding after image-guided breast biopsies: Discontinuing vs. maintaining antithrombotic therapyon May 10, 2023 at 1:34 pm
More information: Melissa Reichman et al, Bleeding Events After Image-Guided Breast Biopsies: Comparison of Patients Temporarily Discontinuing Versus Maintaining Antithrombotic Therapy During ...
- Bleeding after image-guided breast biopsies: Discontinuing vs. maintaining antithrombotic therapyon May 9, 2023 at 5:00 pm
Leesburg, VA, May 10, 2023—According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), frequencies of imaging-apparent and palpable hematoma were not ...
- Length of Prostate Biopsies Is Not Necessarily Compromised by Pooling Multiple Cores in One Paraffin Block: An Observational Studyon April 19, 2023 at 5:00 pm
Individual site-designated biopsies were submitted to our laboratory in 57 (16.6%) cases, and non-specified (pooled) bilateral biopsies were submitted in 287 (83.4%) cases. Of the pooled biopsies ...
via Bing News